Literature DB >> 30100222

Admission heart rate and in-hospital course of patients with Takotsubo syndrome.

Luca Arcari1, Luca Rosario Limite2, Luca Cacciotti3, Matteo Sclafani2, Domitilla Russo2, Ilaria Passaseo3, Giuseppe Marazzi4, Gerardo Ansalone3, Massimo Volpe5, Camillo Autore2, Maria Beatrice Musumeci2.   

Abstract

BACKGROUND: In-hospital course of patients with Takotsubo syndrome (TS) is quite heterogeneous and life-threatening complications are not uncommon in the acute phase. The role of heart rate (HR) as a predictor of prognosis has not been sufficiently investigated in this setting. The study aims to assess the impact of HR at presentation on in-hospital course of patients with TS.
METHODS: The study population included 221 patients with TS enrolled in a multicentric registry. HR at admission was evaluated on the first electrocardiogram. According to tertile distribution of HR at presentation, 3 groups were identified: Group A (HR ≤ 76 beats per minute (bpm), n = 76), Group B (HR 77-95 bpm, n = 74) and Group C (HR > 95 bpm, n = 71). Acute in-hospital complications were defined as occurrence of severe pump failure and major arrhythmias.
RESULTS: 32 (14.4%) patients experienced complicated in-hospital course. HR on admission was significantly higher (108 bpm vs. 85 bpm; p < 0.001) and ejection fraction (EF) lower (35% vs. 40%; p = 0.009) in patients with complications than in those without. Patients in Group C experienced a 5-fold higher rate of complications compared to group A and B. After multivariate analysis, higher HR (odds ratio 1.34 per 10 bpm increase, 95% confidence interval (CI) 1.12-1.59; p = 0.001) and lower EF (odds ratio 1.24 per 5% decrease, 95% CI 1.01-1.54; p = 0.049) remained independently associated with a worse outcome.
CONCLUSION: In a large population with TS, high HR on admission independently predicted complicated in-hospital course.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute pulmonary oedema; Heart rate; Prognosis; Shock; Takotsubo syndrome

Mesh:

Year:  2018        PMID: 30100222     DOI: 10.1016/j.ijcard.2018.07.145

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

Review 1.  Stepwise approach for diagnosis and management of Takotsubo syndrome with cardiac imaging tools.

Authors:  Francesco Santoro; Adriana Mallardi; Alessandra Leopizzi; Enrica Vitale; Thomas Stiermaier; Paolo Trambaiolo; Matteo Di Biase; Ingo Eitel; Natale Daniele Brunetti
Journal:  Heart Fail Rev       Date:  2022-01-18       Impact factor: 4.214

2.  Clinical Characteristics and Long-Term Mortality Rate in Female Patients with Takotsubo Syndrome Compared with Female Patients with ST-Elevation Acute Myocardial Infarction: A Retrospective Study from a Single Center.

Authors:  Laura Massobrio; Alberto Valbusa; Marina Sartini; Giovanni Meliota; Francesca Cavalla; Roberta Miceli; Giulia Vischi; Maria Luisa Cristina; Anna Maria Spagnolo; Roberto Delfino; Francesco Abbadessa; Italo Porto; Claudio Brunelli; Gian Marco Rosa
Journal:  Cardiol Res Pract       Date:  2019-07-30       Impact factor: 1.866

3.  Incidence, determinants and prognostic relevance of dyspnea at admission in patients with Takotsubo syndrome: results from the international multicenter GEIST registry.

Authors:  Luca Arcari; Maria Beatrice Musumeci; Thomas Stiermaier; Ibrahim El-Battrawy; Christian Möller; Federico Guerra; Giuseppina Novo; Enrica Mariano; Luca Rosario Limite; Luca Cacciotti; Raffaella Semeraro; Massimo Volpe; Francesco Romeo; Pasquale Caldarola; Holger Thiele; Ibrahim Akin; Natale Daniele Brunetti; Ingo Eitel; Francesco Santoro
Journal:  Sci Rep       Date:  2020-08-12       Impact factor: 4.379

Review 4.  A systematic review on focal takotsubo syndrome: a not-so-small matter.

Authors:  Giacomo Tini; Luca Rosario Limite; Luca Arcari; Luca Cacciotti; Domitilla Russo; Matteo Sclafani; Claudio Brunelli; Massimo Volpe; Camillo Autore; Maria Beatrice Musumeci
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.